These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29534674)

  • 21. Author´s answer: Biosimilar therapy for inflammatory bowel disease.
    Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
    Rev Esp Enferm Dig; 2014 Jan; 106(1):67-8. PubMed ID: 24689723
    [No Abstract]   [Full Text] [Related]  

  • 22. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.
    Hakizimana A; Ahmed I; Russell R; Wright M; Afzal NA
    World J Gastroenterol; 2017 Jul; 23(25):4473-4479. PubMed ID: 28740335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B; Dignaß A; Schreiber S
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
    Kotze PG; Danese S
    Curr Med Chem; 2019; 26(2):246-247. PubMed ID: 30907307
    [No Abstract]   [Full Text] [Related]  

  • 33. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
    Fiorino G; Fazio M; Danese S
    Expert Rev Clin Immunol; 2016; 12(4):361-3. PubMed ID: 26752540
    [No Abstract]   [Full Text] [Related]  

  • 36. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
    Danese S; Gomollon F;
    J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of Biosimilars in Inflammatory Bowel Diseases.
    Feagins LA; Gold S; Steinlauf AF;
    Am J Gastroenterol; 2024 Feb; 119(2):229-232. PubMed ID: 37566893
    [No Abstract]   [Full Text] [Related]  

  • 38. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The nocebo effect: a clinical challenge in the era of biosimilars.
    Pouillon L; Socha M; Demore B; Thilly N; Abitbol V; Danese S; Peyrin-Biroulet L
    Expert Rev Clin Immunol; 2018 Sep; 14(9):739-749. PubMed ID: 30118338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elective Switching on Biosimilars: Far More Than Nonmedical Switching.
    Cao X; Yuan H; Liang J; Huang H
    Inflamm Bowel Dis; 2022 Jul; 28(7):e101-e102. PubMed ID: 35150261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.